Sulfatinib is a multi-target angio-immuno kinase inhibitor for treating neuroendocrine tumors, selectively targeting FGFR1 and CSF-1R. Here, the authors elucidate the molecular mechanisms behind its binding and kinase selectivity, highlighting interactions with a hydrophobic pocket for FGFR selectivity, and rotatory flexibility to potentially overcome CSF-1RT663I gatekeeper mutation.
- Qianmeng Lin
- Shuyan Dai
- Xiaojuan Chen